370 related articles for article (PubMed ID: 19372179)
1. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
Bodey GP
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
[TBL] [Abstract][Full Text] [Related]
2. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy?
Williams KJ
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i18-20. PubMed ID: 19372175
[TBL] [Abstract][Full Text] [Related]
3. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
Pizzo PA
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
[TBL] [Abstract][Full Text] [Related]
4. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
5. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
[No Abstract] [Full Text] [Related]
6. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
8. Management of the febrile neutropenic patient.
Picazo JJ;
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
[TBL] [Abstract][Full Text] [Related]
9. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis.
Blijlevens NM; Logan RM; Netea MG
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i36-40. PubMed ID: 19372181
[TBL] [Abstract][Full Text] [Related]
10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008.
Bennett JE
J Antimicrob Chemother; 2009 May; 63 Suppl 1(Suppl 1):i23-6. PubMed ID: 19372177
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ;
Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of bacterial infections in neutropenic and immunocompromised patients].
Helbig W; Tauchnitz R
Z Gesamte Inn Med; 1992 Sep; 47(9):417-21. PubMed ID: 1441670
[TBL] [Abstract][Full Text] [Related]
13. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
14. [Bacterial infections in neutropenic patients with cancer].
Matysiak M
Przegl Lek; 2003; 60 Suppl 5():54-7. PubMed ID: 14575008
[TBL] [Abstract][Full Text] [Related]
15. Empiric therapy for febrile neutropenia: what are the choices?
Aoun M
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):507-15. PubMed ID: 17547514
[TBL] [Abstract][Full Text] [Related]
16. Outpatient oral antibiotics for febrile neutropenic cancer patients.
Ouvrier MJ; Thery JC; Blot E
J Clin Oncol; 2006 Dec; 24(35):5614; author reply 5614-5. PubMed ID: 17158551
[No Abstract] [Full Text] [Related]
17. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
[No Abstract] [Full Text] [Related]
18. [Prevention and therapy of infections in tumor patients].
Burgmann H
Wien Med Wochenschr; 2001; 151(24):600-14. PubMed ID: 11820177
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of antibiotics in febrile neutropenic patients with cancer].
Villegas JB; Gavilán MG
Rev Esp Quimioter; 1999 Jun; 12(2):104-6. PubMed ID: 10562669
[No Abstract] [Full Text] [Related]
20. [Therapeutic approach to a patient with febrile neutropenia].
Duraković N; Nemet D
Lijec Vjesn; 2007; 129(10-11):344-50. PubMed ID: 18257335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
